In Patients 12 years and older, 3 pivotal clinical studies of total nasal symptom scores showed
vs azelastine HCI or fluticasone propionate comparators
Dymista demonstrated significantly greater improvement in reflective total nasal symptom relief in patients 12 years and older.1-3
The azelastine HCI and fluticasone propionate comparators used the same device and vehicle as Dymista and are not commercially marketed.1
Data shown are from pivotal study MP 4004. Across all 3 pivotal clinical trials, Dymista provided a significant improvement in rTNSS, ranging from 44% to 64% relative to azelastine HCI or fluticasone propionate comparators, as presented in the Full Prescribing information.1-3
Change from baseline in the placebo-subtracted mean rTNSS for each day (maximum score 24), averaged over the 14-day study period. Percent difference represents the improvement in rTNSS with Dymista relative to azelastine HCI or fluticasone propionate comparators.1-3
References: 1. Dymista [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc., a Viatris Company; 2021. 2. Data on file. Meda Pharmaceuticals Inc., a Viatris Company. 3. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289.e10.